Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Share News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,918.00
Bid: 1,915.00
Ask: 1,921.00
Change: -14.00 (-0.72%)
Spread: 6.00 (0.313%)
Open: 1,926.00
High: 1,926.00
Low: 1,918.00
Prev. Close: 1,932.00
HIK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 3-Pandemic fears pummel European stocks into correction territory

Thu, 27th Feb 2020 09:58

(For a live blog on European stocks, type LIVE/ in an Eikon
news window)

* Travel and leisure, basic resources stocks worst hit

* WPP leads losses on STOXX 600 after bleak forecast

* Standard Chartered, AB InBev latest victims of virus
damage

* Hikma Pharma tops STOXX 600 on annual earnings beat
(Adds details, updates to close)

By Ambar Warrick and Thyagaraju Adinarayan

Feb 27 (Reuters) - European stocks marked their weakest
close in more than four months on Thursday, sinking into
correction territory as a jump in coronavirus cases outside
China deepened fears of an economically damaging pandemic.

Investors typically consider a correction in a security or
index to be a drop of 10% or more from its recent peak.

The pan-European STOXX 600 index, which retreated
3.8% for the day, has fallen more than 10% from a record high
hit on Feb. 19.

While strong earnings had caused investors to pause selling
on Wednesday, a spike in infections outside China, particularly
in Italy, saw markets slip back into red.

"From the unshakeable optimism seen at the beginning of the
year, investors have done a complete U-turn switching from
excessive optimism to outright pessimism in less than a week,"
Michael Hewson, chief market analyst at CMC Markets UK, said.

Thursday's sell-off saw more than 97% of the pan-European
STOXX 600 index's constituents trading red, with basic
resources stocks among the worst performers as commodity
prices plunged amid fears of sustained disruptions in the global
supply chain.

"The sell-off in the base metals complex over the last few
days largely reflects the heightened risk-off sentiment or
'fear-factor' across broader riskier assets," Wenyu Yao, senior
commodities strategist at ING wrote in a note.

London-listed miner Evraz Plc was the worst
performing stock in the sector after it posted weak 2019
earnings.

Travel stocks also plummeted, with casino operator
Evolution Gaming Group leading declines. The sector
has shed nearly 15% this week, underperforming its peers by a
wide margin.

Standard Chartered fell 3.5% after the bank said a
key earnings target would take longer to meet as the epidemic
adds to headwinds in China and Hong Kong. The broader bank
sector was also pressured by a drop in bond yields.

The world's largest beer maker, Anheuser-Busch InBev
, plunged nearly 11% after it forecast muted growth in
2020, due in part to the outbreak.

Advertising major WPP tumbled 16%, marking its worst
day since August 1992, after saying it would target flat organic
growth and profit margins in 2020. The stock was the worst
performer on the STOXX 600.

Italian shares, which entered correction territory
on Wednesday, fell 2.7% as the country reported another 100
coronavirus cases nationwide, taking the total to more than 400.

In a sole bright spot, Hikma Pharmaceuticals rose
4.6%, topping the STOXX 600 after it beat expectations with its
annual earnings.
(Reporting by Sruthi Shankar in Bengaluru and Danilo Masoni in
Milan
Editing by Sriraj Kalluvila, Giles Elgood and Frances Kerry)

More News
17 Jan 2022 09:01

TOP NEWS: Hikma Pharmaceutical acquires Teligent for USD45.8 million

TOP NEWS: Hikma Pharmaceutical acquires Teligent for USD45.8 million

Read more
17 Jan 2022 09:00

TOP NEWS: Hikma Pharmaceutical acquires Teligent for USD45.8 million

TOP NEWS: Hikma Pharmaceutical acquires Teligent for USD45.8 million

Read more
17 Jan 2022 07:49

LONDON MARKET PRE-OPEN: Unilever sees good fit in GSK Consumer Health

LONDON MARKET PRE-OPEN: Unilever sees good fit in GSK Consumer Health

Read more
17 Jan 2022 07:08

Hikma buys Teligent Canadian assets for $47.75m

(Sharecast News) - Hikma Pharmaceuticals on Monday said it had agreed to buy the Canadian assets of Teligent for $45.75m after the US firm filed for Chapter 11 bankruptcy last year.

Read more
10 Jan 2022 07:44

LONDON MARKET PRE-OPEN: Plus500 hails 2021 and mulls new share buyback

LONDON MARKET PRE-OPEN: Plus500 hails 2021 and mulls new share buyback

Read more
10 Jan 2022 07:24

Hikma launches new US injectables unit

(Sharecast News) - Hikma Pharmaceuticals on Monday said it was expanding its injectables business with the launch of a new outsourced sterile compounding business in the US.

Read more
21 Dec 2021 15:55

Arecor flags milestone payment from Hikma in first half of next year

(Sharecast News) - Biopharmaceutical company Arecor Therapeutics updated the market on its ongoing exclusive agreement with Hikma Pharmaceuticals to co-develop a new, ready-to-use injectable medicine on Tuesday.

Read more
9 Dec 2021 09:25

Hikma adds two biosimilars to portfolio with Gedeon Richter agreement

Hikma adds two biosimilars to portfolio with Gedeon Richter agreement

Read more
9 Dec 2021 08:32

Hikma strikes exclusive license agreement with Richter for denosumab

(Sharecast News) - Drugmaker Hikma Pharmaceuticals has entered into an exclusive license agreement with Gedeon Richter to commercialise the latter's denosumab products in the US.

Read more
4 Nov 2021 09:03

TOP NEWS: Hikma confirms 2021 guidance amid strong performance

TOP NEWS: Hikma confirms 2021 guidance amid strong performance

Read more
4 Nov 2021 07:58

Hikma reports solid trading in year to date

(Sharecast News) - Hikma Pharmaceuticals reiterated full-year guidance as the company reported solid trading across its business.

Read more
1 Nov 2021 13:52

Citi sees room for upside surprise on sales at Hikma Pharmaceuticals

(Sharecast News) - Analysts at Citi reiterated their 'buy' stance for shares of Hikma Pharmaceuticals ahead of the company's trading statement due out later in the same week.

Read more
28 Oct 2021 16:12

UK earnings, trading statements calendar - next 7 days

UK earnings, trading statements calendar - next 7 days

Read more
20 Oct 2021 09:51

LONDON BROKER RATINGS: BofA cuts Hammerson and upgrades Capco

LONDON BROKER RATINGS: BofA cuts Hammerson and upgrades Capco

Read more
27 Sep 2021 12:14

LONDON MARKET MIDDAY: Gains ebb; crunch time for US spending bills

LONDON MARKET MIDDAY: Gains ebb; crunch time for US spending bills

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.